Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Completed · Phase 1

Conditions studied: Lung Cancer, Malignant Mesothelioma, Metastatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tumors affecting the lungs.

Key facts

Study ID

NCT00020124

Run by

National Institutes of Health Clinical Center (CC)

Starts

2000-06-01

Expected to finish

2002-12-01

Last updated by the study team

2012-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.